Explore Pro Medicus's Fair Values from the Community and select yours

Pro Medicus (ASX:PME) Full Year 2025 Results

Key Financial Results

Revenue: AU$213.0m (up 32% from FY 2024). Net income: AU$115.2m (up 39% from FY 2024). Profit margin: 54% (up from 51% in FY 2024). The increase in margin was driven by higher revenue.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.ASX:PME Earnings and Revenue History August 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pro Medicus Earnings Insights

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare Services industry in Australia.

Performance of the Australian Healthcare Services industry.

The company's shares are down 1.3% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Pro Medicus' balance sheet health.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments